Michael Lytton is joining another former Biogen Idec Inc. colleague in Toronto to lead Patheon Inc. (TSX: PTI), a pharmaceutical contract development and manufacturing services firm. Lytton will take the role of executive vice president, corporate development and strategy and general counsel; he will report to company CEO Jim Mullen, the former CEO of Biogen Idec, who left the Cambridge biotech  in January 2010.
Lytton previously held a similar role at Biogen Idec, where he was executive vice president, corporate and business development. Before Biogen, he worked as a general partner with venture capital firm Oxford Bioscience Partners. He also was a lawyer for 17 years, serving as an executive committee member of Edwards Angell Palmer & Dodge and as a partner of Wilmer Hale.